ABSTRACT
BACKGROUND: Ablation of atrial fibrillation (AF), both cryoablation ablation (CBA) and radiofrequency catheter ablation (RFCA), have demonstrated to be safe and effective. About 1 in 3 patients may face a redo due to recurrence and the best technique is unknown. The aim of this study is to assess the efficacy of CBA as a repeat procedure in patients with prior CBA or RFCA. METHODS: A nation-wide CBA registry (RECABA) was analyzed and patients were compared who had previously undergone CBA (Prior-CB) or RFCA (Prior-RF). The primary endpoint was AF recurrence at 12 months after a 3-month blanking period. A survival analysis was performed, univariate and multivariate Cox models were also built. RESULTS: Seventy-four patients were included. Thirty-three (44.6%) were in the Prior-CB group and 41 (55.4%) in the Prior-RF. There were more reconnected pulmonary veins in the Prior-RF than in Prior-CB group (40.4% vs.16.5%, p = 0.0001). The 12-month Kaplan-Meier estimate of freedom from AF recurrence after the blanking period was 61.0% (95% confidence interval [CI] 41.4-75.8%) in the Prior-CB, and 89.2% (95% CI 73.6-95.9%) in the Prior-RF group (p = 0.002). Multivariate Cox regression pointed Prior-CB as the sole independent predictor of AF recurrence, with an adjusted HR of 2.67 (95% CI 1.05-6.79). CONCLUSIONS: Repeat CBA shows higher rates of AF recurrences compared to CBA after a previous RFCA despite presenting less reconnected veins at the procedure. These data suggest that patients with AF recurrence after CBA may benefit from other ablation techniques after a recurrence. RECABA is registered at clinicaltrials.gov with the Unique Identifier NCT02785991.
Subject(s)
Cardiology , Heart Diseases , Follow-Up Studies , Humans , Primary Health Care , Referral and ConsultationSubject(s)
COVID-19 , Myocardial Infarction , Humans , Myocardial Infarction/epidemiology , Pandemics , Time-to-TreatmentABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Echocardiography, Stress/methods , Acute Coronary Syndrome/diagnostic imaging , Atropine/administration & dosage , Practice Patterns, Physicians' , Ambulatory Care/methodsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Quarantine/statistics & numerical data , Coronavirus Infections/epidemiology , Immobilization/adverse effects , Pulmonary Embolism/epidemiology , Venous Thrombosis/epidemiology , Pandemics/statistics & numerical data , Emergency Service, Hospital/statistics & numerical data , Risk FactorsSubject(s)
Coronary Artery Disease , Echocardiography, Stress , Coronary Angiography , Humans , SyndromeSubject(s)
Betacoronavirus , Coronavirus Infections/complications , Coronavirus Infections/physiopathology , Electrocardiography/instrumentation , Pneumonia, Viral/complications , Pneumonia, Viral/physiopathology , Aged , COVID-19 , Clinical Protocols , Coronavirus Infections/therapy , Female , Hospitalization , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/therapy , SARS-CoV-2Subject(s)
Coronavirus Infections/complications , Pneumonia, Viral/complications , Pulmonary Embolism/etiology , Quarantine , Adult , Aged , Aged, 80 and over , COVID-19 , Coronavirus Infections/epidemiology , Female , Humans , Infection Control , Male , Middle Aged , Pandemics , Pneumonia, Viral/epidemiology , Pulmonary Embolism/epidemiology , Risk Factors , Sedentary Behavior , Spain/epidemiologyABSTRACT
BACKGROUND: Andersen-Tawil Syndrome type 1 (ATS1) is a rare arrhythmogenic disorder, caused by loss-of-function mutations in the KCNJ2 gene. We present here the largest cohort of patients with ATS1 with outcome data reported. OBJECTIVES: This study sought to define the risk of life-threatening arrhythmic events (LAE), identify predictors of such events, and define the efficacy of antiarrhythmic therapy in patients with ATS1. METHODS: Clinical and genetic data from consecutive patients with ATS1 from 23 centers were entered in a database implemented at ICS Maugeri in Pavia, Italy, and pooled for analysis. RESULTS: We enrolled 118 patients with ATS1 from 57 families (age 23 ± 17 years at enrollment). Over a median follow-up of 6.2 years (interquartile range: 2.7 to 16.5 years), 17 patients experienced a first LAE, with a cumulative probability of 7.9% at 5 years. An increased risk of LAE was associated with a history of syncope (hazard ratio [HR]: 4.54; p = 0.02), with the documentation of sustained ventricular tachycardia (HR 9.34; p = 0.001) and with the administration of amiodarone (HR: 268; p < 0.001). The rate of LAE without therapy (1.24 per 100 person-years [py]) was not reduced by beta-blockers alone (1.37 per 100 py; p = 1.00), or in combination with Class Ic antiarrhythmic drugs (1.46 per 100 py, p = 1.00). CONCLUSIONS: Our data demonstrate that the clinical course of patients with ATS1 is characterized by a high rate of LAE. A history of unexplained syncope or of documented sustained ventricular tachycardia is associated with a higher risk of LAE. Amiodarone is proarrhythmic and should be avoided in patients with ATS1.
